Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Understanding variations in SARS-CoV-2 evolution and clearance by immunodeficiency status

Researchers describe the virological range of persistent SARS-CoV-2 infection in immunosuppressed individuals.

7 Aug 2023

People living with HIV respond well to COVID-19 infection and vaccination

Researchers examine the antibody response to natural infection or COVID-19 vaccination in individuals living with HIV infection.

7 Aug 2023

Cryo-EM structures and functions of potent bispecific antibodies against multiple Omicron sublineages

Researchers characterizes the structures and functions of potent bispecific antibodies against multiple Omicron subvariants using Cryo-EM.

3 Aug 2023

New treatment offers hope for children suffering from rare skin condition

It’s a beautiful moniker, but for Australia’s ‘butterfly children’ it belies a devastating reality filled with enormous pain and suffering caused by a rare skin condition – Epidermolysis Bullosa (EB).

2 Aug 2023

New study spotlights effective strategy against COVID-19 variants: the E7 monoclonal antibody

Researchers developed potent monoclonal antibodies from a severe acute respiratory syndrome coronavirus (SARS-CoV) survivor.

1 Aug 2023

Monoclonal antibody shows promise in slowing progression of ALS

New research reveals a type of monoclonal antibody already tested in certain forms of cancer may be a promising treatment in stopping the progression of amyotrophic lateral sclerosis, or ALS, a fatal neurodegenerative disease.

31 Jul 2023

Experts weigh benefits and risks of new Alzheimer's disease therapies

New therapies for early Alzheimer's disease, monoclonal antibodies that remove amyloid-β plaques in the brain, are bringing hope to people whose lives have been affected by the disease.

26 Jul 2023

Tumor-derived GDF-15 suppresses immunotherapy response

Researchers evaluate the impact of tumor-derived GDF-15 on responses to anti-PD-1 immunotherapy.

26 Jul 2023

Brazilian researchers identify new way to stop excessive inflammation in COVID-19

Researchers at the University of São Paulo (USP) in Brazil have identified a new class of molecules capable of stopping the excessive inflammation typical of the severe form of COVID-19 without impairing the immune response to SARS-CoV-2, the virus that causes the disease.

25 Jul 2023

Donanemab shows promise in slowing Alzheimer's disease

With yet a third new Alzheimer's drug expected to be approved by the Food and Drug Administration (FDA), the field is beginning to show progress in the fight to slow the disease.

17 Jul 2023

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

Researcher receives $2.7 million grant to study lingering Lyme disease symptoms

An estimated 1,200 Americans, on average, are diagnosed with Lyme disease each day. Some of those patients continue to experience negative effects, even after treatment.

14 Jul 2023

COVID antiviral treatments underused in nursing homes, study finds

Nursing homes were a key battleground during the COVID pandemic and prioritized for distribution of PPE, vaccines, and COVID testing kits.

14 Jul 2023

New drug could overcome resistance to CDK4/6 inhibitors in breast cancer

Brest cancer is the most common cancer in women. Among breast tumors that spread to other organs (develop metastasis), 70% belong to a variant, called luminal, whose cells are sensitive to the female sex hormones estrogen and progesterone. In fact, the tumor forms when these hormones order the cells to divide.

14 Jul 2023

Difficult transmembrane protein targets for therapeutic antibodies

In this interview, News-Medical talks to Sylvia Xie, product scientist at Sino Biological, about the ongoing emergence of transmembrane proteins as targets for therapeutic antibodies.

From Sino Biological Inc. 12 Jul 2023

AGS supports CMS decision to require registry data for monoclonal antibodies for Alzheimer's disease

The American Geriatrics Society (AGS) supports the recently announced decision from the Centers for Medicare and Medicaid Services (CMS) to require the collection of real-world information via a registry to study monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease.

11 Jul 2023